Composition containing dl-alpha-tocopherol 2-l-ascorbic acid phosphate diester alkali metal salt
By using potassium dl-α-tocopherol 2-L-ascorbic acid phosphate diester in oral compositions, the problems of prevention and progression of periodontal disease and dental caries are solved, and the protection of oral mucosal epithelial barrier function and inhibition of MMP activity are achieved.
Patent Information
- Application Number
- CN202380031170.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-30
- Filing Date
- 2023-02-24
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, there are no reports on the effects of dl-α-tocopherol 2-L-ascorbic acid phosphate diester in the oral region, especially regarding the lack of effective compositions for the prevention and inhibition of periodontal disease.
Using dl-α-tocopherol 2-L-ascorbic acid phosphate diester alkali metal salt, especially dl-α-tocopherol 2-L-ascorbic acid phosphate diester potassium salt, as the main component, a composition for periodontal disease, oral mucositis and dental caries was developed by inhibiting the disruption of oral mucosal epithelial barrier function and matrix metalloproteinase (MMP) activity.
It effectively inhibits the destruction of the oral mucosal epithelial barrier function and MMP activity, thereby preventing the onset and progression of periodontal disease, inhibiting the occurrence of oral mucositis, and preventing the development of dental caries.
Smart Images

Figure CN118973545A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a composition containing an alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate, etc. Background Art
[0002] dl-α-Tocopherol 2-L-ascorbyl phosphate diester (sometimes referred to as "EPC" in this specification) is a compound in which ascorbic acid (vitamin C) and tocopherol (vitamin E) are ester-bonded via phosphoric acid, has antioxidant and moisturizing effects, and can be used in cosmetics such as hair growth agents (Patent Document 1).
[0003] There are no reports on what effects EPC may exert in the oral region.
[0004] Prior art literature
[0005] Patent Literature
[0006] Patent Document 1: International Publication No. 2020 / 196852
[0007] Non-patent literature
[0008] Non-patent literature 1: Periodontol 2000. 2015 Oct; 69(1): 7-17. Molecular aspects of the pathogenesis of periodontitis
[0009] Non-patent literature 2: J Periodontal Res. 2016 Dec; 51(6): 748-757. Influence of retinoic acid on human gingival epithelial barriers
[0010] Non-patent literature 3: Int J Dent. 2012; 2012: 821383. Published online 2012 Jul 26. Host-Bacteria Crosstalk at the Dentogingival Junction
[0011] Non-patent literature 4: Arch Oral Biol. 2016Jun;66:30-7. The traditional Japanese medicine hangeshashinto alleviates oral ulcer-induced pain in a rat model.
[0012] Non-patent document 5: Aust Dent J. 2009 Dec; 54(4): 347-54. Localization of matrix metalloproteinases (MMPs-2, 8, 9 and 20) in normal and carious dentine. Summary of the invention
[0013] Problem that the invention aims to solve
[0014] An object of the present invention is to provide a composition capable of preventing the onset and / or suppressing the progression of periodontal disease.
[0015] Solutions for solving problems
[0016] The present inventors have found that dl-α-tocopherol 2-L-ascorbic acid diester alkali metal salt inhibits the destruction of the oral mucosal epithelial barrier function and inhibits the activity of matrix metalloproteinase (MMP), and have further repeatedly improved it.
[0017] The present invention includes, for example, the subject matters described in the following items.
[0018] Item 1.
[0019] An oral composition containing dl-α-tocopherol 2-L-ascorbic acid diester phosphate alkali metal salt (excluding oral compositions containing at least one selected from the group consisting of polyoxyethylene alkylphenyl ether, polyoxyethylene alkyl ether and polyoxyethylene fatty acid ester).
[0020] Item 2.
[0021] A composition for preventing periodontal disease contains dl-α-tocopherol 2-L-ascorbic acid diester phosphate alkali metal salt.
[0022] Item 3.
[0023] The composition according to item 1 or 2, comprising 0.001 to 1% by mass of dl-α-tocopherol 2-L-ascorbic acid diester alkali metal salt.
[0024] Item 4.
[0025] The composition according to any one of items 1 to 3, wherein the alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate is dl-α-tocopherol 2-L-ascorbic acid diester phosphate potassium salt.
[0026] Item 5.
[0027] The composition according to any one of items 1 to 4, which is for use against oral mucositis or against dental caries.
[0028] Item 6.
[0029] The composition according to any one of items 1 to 5, which is used for enhancing the barrier function of oral mucosal epithelium.
[0030] Item 7.
[0031] The composition according to any one of Items 1 to 6, which is used for inhibiting matrix metalloproteinase activity in the oral cavity.
[0032] Item 8.
[0033] Use of dl-α-tocopherol 2-L-ascorbic acid diester alkali metal salt in the manufacture of an anti-periodontal disease composition, an anti-oral mucositis composition, an anti-caries composition, a composition for enhancing the barrier function of oral mucosal epithelium, or a composition for inhibiting matrix metalloproteinase activity in the oral cavity.
[0034] Item 9.
[0035] The use according to item 8, wherein the alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate is dl-α-tocopherol 2-L-ascorbic acid diester phosphate potassium salt.
[0036] Item 10.
[0037] The use according to item 8 or 9, characterized in that the content of the alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate in the composition is 0.001 to 1% by mass.
[0038] Effects of the Invention
[0039] The composition of the present invention can inhibit the destruction of the barrier function of the oral mucosal epithelium and / or inhibit the activity of MMP, thereby preventing the onset of periodontal disease and / or inhibiting the progression of periodontal disease. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 The permeability (%) when EPC-K (dl-α-tocopherol 2-L-ascorbyl phosphate diester potassium salt) was contained is shown.
[0041] Figure 2 The transmittance (%) when EPC-K is contained is shown.
[0042] Figure 3 The permeability (%) when EPC-K, APM (Mg ascorbyl phosphate), VC (ascorbic acid), VEA (tocopheryl acetate), and VEN (tocopheryl nicotinate) are shown.
[0043] Figure 4 The results of measuring MMP-8 activity are shown.
[0044] Figure 5 The results of measuring MMP-1 activity are shown.
[0045] Figure 6 The cell survival rate (%) when sorbitan 60 tetraoleate, diethyl sebacate, polyoxyethylene hydrogenated castor oil 10, polyoxyethylene (9) lauryl ether, and polyoxyethylene (20) stearyl ether were contained is shown.
[0046] Figure 7 The cell survival rate (%) when polyoxyethylene (9) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (20) stearyl ether, polyoxyethylene (10) octylphenyl ether and polyoxyethylene glycol monolaurate were contained is shown. DETAILED DESCRIPTION
[0047] The various embodiments of the present invention are described in further detail below.
[0048] The composition included in the present invention contains an EPC alkali metal salt. In this specification, this composition may be referred to as "the composition of the present invention".
[0049] dl-α-tocopherol 2-L-ascorbyl phosphate diester (EPC) is a compound in which ascorbic acid (vitamin C) and tocopherol (vitamin E) are linked by an ester bond via phosphoric acid, and is also called ascorbyl tocopheryl phosphate. The chemical formula is shown below.
[0050]
[0051] Examples of the EPC alkali metal salt include EPC potassium salt, EPC sodium salt, and EPC lithium salt. Among them, EPC potassium salt is preferred.
[0052] In addition, the EPC alkali metal salt may be a monosalt or a disalt.
[0053] The content of the EPC alkali metal salt contained in the composition of the present invention can be, for example, about 0.001 to 1% by mass. The upper limit or lower limit of the range can be, for example, about 0.002, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 or 0.9% by mass. More specifically, for example, it can be about 0.002 to 0.5% by mass, or about 0.005 to 0.3% by mass.
[0054] The composition of the present invention can exert the effect of suppressing the destruction of the barrier function of the oral mucosal epithelium by including the EPC alkali metal salt. Therefore, the composition of the present invention can be preferably used for the purpose of enhancing the barrier function of the oral mucosal epithelium. As the oral mucosal epithelium, it is not particularly limited, and the epithelium constituting the masticatory mucosa (such as gums, etc.) (such as gingival epithelium such as junctional epithelium, gingival sulcus epithelium, etc.), the epithelium constituting the coating mucosa (such as buccal mucosa, etc.), and the epithelium constituting the special mucosa (such as tongue mucosa, etc.) can be listed.
[0055] In addition, the composition of the present invention exerts the effect of inhibiting the activity of MMP by containing EPC alkali metal salt. Therefore, the composition of the present invention can be preferably used for the purpose of inhibiting the activity of matrix metalloproteinase (MMP) in the oral cavity. It should be noted that the composition of the present invention can inhibit the activity of the produced neutrophil collagenase because it exerts the effect of inhibiting the activity of MMP. As the matrix metalloproteinase (MMP) in the oral cavity, for example, MMP-1, 2, 3, 8, 9, 13, etc. can be listed. Among them, MMP-1 and 8 are preferred. It should be noted that MMP-1 (EC 3.4.24.7) is also called interstitial collagenase. In addition, MMP-8 (EC3.4.24.34) is also called neutrophil collagenase.
[0056] In addition, it is reported that the gingival epithelium forms a barrier against invading microorganisms to protect periodontal tissues from infection (non-patent literature 1). It is also reported that periodontal pathogens such as Porphyromonas gingivalis can secrete bacterial proteases to destroy the gingival epithelium and achieve invasion into the periodontal tissue (non-patent literature 2). It is known that with the invasion of periodontal pathogens into the tissue, immune cells such as neutrophils gather to remove them, and the production of MMPs increases. MMPs are proteolytic enzymes that decompose the extracellular matrix (such as collagens such as type I collagen, type II collagen, type III collagen, etc.), whereby periodontal tissues are destroyed and periodontal disease progresses. In fact, an increase in MMP-1, 2, 3, 8, 9 and 13 was observed in the gingival crevicular fluid (GCF) of periodontal patients (non-patent literature 3).
[0057] The composition of the present invention plays the effect of suppressing the destruction of the barrier function of the oral mucosal epithelium and / or the effect of suppressing the activity of MMP by comprising EPC alkali metal salt, therefore can be preferably used as oral composition, particularly can be preferably used for anti-periodontal disease purposes. That is, the composition of the present invention can prevent periodontal bacteria from entering the periodontal tissue by enhancing the barrier function of the oral mucosal epithelium. In addition, the composition of the present invention can prevent the destruction of the periodontal tissue by suppressing the matrix metalloproteinase activity in the oral cavity. Therefore, it can be expected to be applicable to the situation of all periodontal diseases from the initial stage to the progress state. It should be noted that in this specification, "anti-periodontal disease" refers to the prevention of the morbidity of periodontal disease and / or suppresses the progress of periodontal disease.
[0058] It is reported in addition that when ulcers are formed on the oral mucosa due to the side effects of bites, burns, chemotherapy or radiotherapy, the barrier function of the epithelium is lost, causing oral bacterial infection (oral mucositis, non-patent literature 4). The composition of the present invention plays the effect of suppressing the destruction of the oral mucosal epithelial barrier function by containing EPC alkali metal salts, so it can be preferably used for anti-oral mucositis purposes. It should be noted that in this specification, "anti-oral mucositis" refers to the morbidity of preventing oral mucositis and / or suppresses the progress of oral mucositis.
[0059] In addition, dentin contains about 20% collagen as organic matter, and when dentin caries progresses, it is accompanied by demineralization and collagen decomposition. As collagen decomposition, it is believed that MMPs in saliva penetrate into dentin and decompose it (non-patent literature 5). The composition of the present invention exerts the effect of suppressing the activity of MMP by containing EPC alkali metal salts, so it can be preferably used for anti-caries purposes. It should be noted that in this specification, "anti-caries" refers to the prevention of the onset of caries and / or the inhibition of the progress of caries.
[0060] Examples of the application targets of the composition of the present invention include mammals including humans (eg, dogs, cats, mice, rats, sheep, horses, cattle, monkeys, etc.), etc. Among them, humans are preferred.
[0061] The subjects to whom the composition of the present invention can be applied are not limited to, for example, patients with periodontal disease or persons suspected of having periodontal disease; patients with oral mucositis or persons suspected of having oral mucositis; patients with dental caries or persons suspected of having dental caries; persons with weakened oral mucosal epithelial barrier function; persons with hyperactivity of matrix metalloproteinases in the oral cavity, etc., and may also be healthy persons (for example, persons who want to prevent the onset of periodontal disease, persons who want to inhibit the progression of periodontal disease, persons who want to prevent the onset of oral mucositis, persons who want to inhibit the progression of oral mucositis, persons who want to prevent the onset of dental caries, persons who want to inhibit the progression of dental caries, etc.), etc.
[0062] The composition of the present invention may be, for example, a solid composition, a liquid composition, etc. In addition, the composition of the present invention (particularly an oral composition) may be prepared in the form of an ointment, a paste, a paste, a gel, a liquid, a spray, a mouthwash, a liquid toothpaste, a toothpaste, a chewing gum, a tablet, a drop, etc. according to a conventional method. Among them, an ointment, a paste, a gel, a liquid, a mouthwash, a liquid toothpaste, and a toothpaste are preferred.
[0063] The composition of the present invention may contain, in addition to the EPC alkali metal salt, one or more of any ingredients that can be formulated in oral compositions in the art, such as surfactants, flavoring agents, sweeteners, wetting agents, binders, preservatives, colorants, pH adjusters, and medicinal ingredients other than EPC.
[0064] For example, as a surfactant, at least one selected from the group consisting of a nonionic surfactant, an anionic surfactant and an amphoteric surfactant may be added. Specifically, for example, as a nonionic surfactant, sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; glycerol fatty acid esters; sorbitan fatty acid esters; monoglycerides; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan, etc. may be mentioned. As anionic surfactants, sulfate ester salts such as sodium lauryl sulfate and sodium polyoxyethylene lauryl ether sulfate; sulfosuccinates such as sodium lauryl sulfosuccinate and sodium polyoxyethylene lauryl ether sulfosuccinate; acylamino acid salts such as sodium cocoyl sarcosinate and sodium lauroyl methyl alanine; sodium cocoyl methyl taurine, etc. may be mentioned. As amphoteric surfactants, there can be mentioned betaine-type surfactants such as lauryl dimethylaminoacetic acid betaine and coconut fatty acid amide propyl dimethylaminoacetic acid betaine; imidazoline-type surfactants such as sodium N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine, etc. These surfactants can be formulated alone or in combination of two or more. The amount thereof is usually 0.1 to 5% by mass relative to the total amount of the composition.
[0065] It should be noted that the composition of the present invention may not contain at least one surfactant selected from the group consisting of polyoxyethylene alkyl phenyl ether, polyoxyethylene alkyl ether and polyoxyethylene fatty acid ester. In particular, the composition of the present invention may be a composition that does not contain polyoxyethylene alkyl phenyl ether, polyoxyethylene alkyl ether and polyoxyethylene fatty acid ester.
[0066] Examples of the polyoxyethylene alkylphenyl ethers include polyoxyethylene alkylphenyl ethers having an average addition mole number of ethylene oxide of 1 to 40 and an alkyl group having 7 to 30 carbon atoms. Examples of the polyoxyethylene alkyl ethers include polyoxyethylene alkyl ethers having an average addition mole number of ethylene oxide of 1 to 40 and an alkyl group having 1 to 18 carbon atoms. Examples of the polyoxyethylene fatty acid esters include polyoxyethylene fatty acid esters having an average addition mole number of ethylene oxide of 1 to 40 and an alkyl group having 1 to 20 carbon atoms.
[0067] In addition, as flavoring agents, for example, menthol, carvone, anethole, eugenol, methyl salicylate, limonene, ocimene, n-decanol, citronellol, α-terpineol, methyl acetate, citronellyl acetate, methyl eugenol, eucalyptol, linalool, ethyl linalool, thymol, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, perilla oil, wintergreen oil, clove oil, eucalyptus oil, allspice oil, d-camphor, d-borneol, anise oil, cinnamon oil, cinnamon aldehyde, peppermint oil, vanillin and other flavoring agents can be used. These can be used alone or in combination of two or more, and can be blended in an amount of, for example, 0.001 to 1.5% by mass relative to the total amount of the composition.
[0068] In addition, as sweeteners, for example, saccharin sodium, acesulfame potassium, stevioside, neohesperidin dihydrochalcone, perilla, thaumatin, aspartame, p-methoxycinnamaldehyde, etc. can be used. These can be used alone or in combination of two or more, and can be blended in an amount of, for example, 0.01 to 1% by mass relative to the total amount of the composition.
[0069] Furthermore, as the wetting agent, sorbitol, ethylene glycol, propylene glycol, glycerin, 1,3-butylene glycol, polypropylene glycol, xylitol, maltitol, lactitol, polyoxyethylene glycol, etc. may be blended alone or in combination of two or more.
[0070] Examples of the binder include cellulose derivatives such as sodium carboxymethylcellulose, carboxymethylethylcellulose salt, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, methylcellulose, ethylcellulose, crystalline cellulose, and crystalline cellulose·sodium carboxymethylcellulose; macromolecules produced by microorganisms such as xanthan gum; natural macromolecules or natural rubbers such as tragacanth gum, karaya gum, gum arabic, carrageenan, dextrin, agar, pectin, pullulan, gellan gum, locust bean gum, and sodium alginate; synthetic macromolecules such as polyvinyl alcohol, polyvinyl pyrrolidone, carboxyvinyl polymer, polyvinyl methyl ether, and sodium polyacrylate; inorganic binders such as thickening silica and Veegum, and cationic binders such as chloride O-[2-hydroxy-3-(trimethylamino)propyl]hydroxyethylcellulose. These binders may be used alone or in combination of two or more.
[0071] As preservatives, parabens such as methylparaben, ethylparaben, propylparaben, butylparaben, etc., sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride, etc. can be added. These can be used alone or in combination of two or more.
[0072] As coloring agents, legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, Green No. 3, mineral pigments such as Ultramarine, Enhanced Ultramarine, Prussian Blue, titanium oxide, etc. can be added. These can be used alone or in combination of two or more.
[0073] As the pH adjuster, citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically acceptable salts thereof, sodium hydroxide, etc. can be mixed. These can be mixed alone or in combination of two or more in such a manner that the pH of the composition reaches a range of 4 to 8, preferably 5 to 7. The mixing amount of the pH adjuster can be, for example, 0.01 to 2 mass %.
[0074] It should be noted that the composition of the present invention may further contain a pharmaceutical ingredient other than the EPC alkali metal salt, either alone or in combination of two or more, wherein the pharmaceutical ingredient is a vitamin E such as dl-α-tocopheryl acetate, tocopheryl succinate, or tocopheryl nicotinate, an amphoteric bactericide such as dodecyldiaminoethylglycine, a nonionic bactericide such as triclosan and isopropylmethylphenol, an anionic bactericide such as sodium lauroyl sarcosinate, a cationic bactericide such as cetylpyridinium chloride, chlorhexidine hydrochloride, benzalkonium chloride, benzethonium chloride, etc. Bactericides, dextranase, amylase, protease, water-insoluble dextranase, lysozyme, enzymes such as lyticenzyme, alkali metal monofluorophosphates such as sodium monofluorophosphate and potassium monofluorophosphate, fluorides such as sodium fluoride and stannous fluoride, tranexamic acid, ε-aminocaproic acid, aluminum chlorohydroxyallantoin, dihydrocholesterol, hibiscus phenol, glycyrrhetinic acid, glycyrrhizic acid, sodium copper chlorophyllin, glycerophosphate, chlorophyll, sodium chloride, carotidone, allantoin, carbaclot, potassium nitrate, palatinitol, etc.
[0075] In addition, as a base, alcohols, silicon, apatite, white vaseline, paraffin, liquid paraffin, microcrystalline wax, squalane, Plastibase, etc. can also be added. These can be used alone or in combination of two or more.
[0076] The composition of the present invention can be prepared based on a known method for producing such a composition. For example, it can be prepared by appropriately mixing an EPC alkali metal salt and other components used as required.
[0077] It should be noted that, in this specification, "comprising" also includes "consisting essentially of" and "consisting of." In addition, the present invention includes all of the arbitrary combinations of the constituent requirements described in this specification.
[0078] In addition, when the various characteristics (properties, structures, functions, etc.) described in the above-mentioned embodiments of the present disclosure specify the subject matter included in the present disclosure, any combination is possible. That is, the present disclosure includes all the subject matter consisting of all combinations of the various characteristics that can be combined as described in this specification.
[0079] Example
[0080] The contents of the present disclosure are specifically described using the following experimental examples. However, the present disclosure is not limited to them in any way. In the following, except for the cases specifically mentioned, the experiments were carried out under atmospheric pressure and normal temperature conditions. In addition, except for the cases specifically mentioned, "%" means "mass %". In addition, the blending amount values of each component recorded in each table also represent "mass %" when there is no special statement.
[0081] 1. Epithelial barrier function evaluation test
[0082] Cell preparation
[0083] Epi4 cells of the gingival epithelial cell line were cultured on Transwell until confluence. At this time, Epi4 cells were cultured using a medium supplemented with 1% of Supplemental S7 (Thermo Fisher) in Epilife (Thermo Fisher). It should be noted that in the present invention, the above-mentioned medium is sometimes referred to as "cell medium". In addition, Transwell is a tool designed to evaluate cell permeability in a manner in which a plug is suspended in the middle of a well.
[0084] Bacterial preparation
[0085] Porphyromonas gingivalis W83 was cultured in a modified GAM medium (Nissui Pharmaceutical Co., Ltd.), and then centrifuged at 10,000 rpm to recover the recovered Pg bacteria. 600 The concentration was adjusted using the cell culture medium so that the concentration was 1.0.
[0086] Material preparation
[0087] The cells were cultured in a medium containing 2.5% DMSO. Figure 1 to Figure 3 Each evaluation material was added at the concentration described, thereby preparing a culture medium containing each evaluation material. The evaluation materials used were EPC-K (dl-α-tocopherol 2-L-ascorbyl phosphate diester potassium salt), APM (ascorbyl phosphate magnesium), VC (ascorbic acid), VEA (tocopheryl acetate) and VEN (tocopheryl nicotinate).
[0088] Barrier function assessment
[0089] The cell culture medium was removed from Epi4 cells cultured on Transwell, and 300 μl of the prepared culture medium containing each evaluation material was added, and incubated at 37°C and 5% CO2 for 1 hour. At this time, a medium without the evaluation material was added as a control.
[0090] Then, 100 μl of the prepared Pg bacterial solution was added and incubated at 37°C and 5% CO2 for 2 hours. At this time, controls were prepared in which the Pg bacterial solution was added and incubated (Pg(+)) and in which only a medium containing no Pg bacteria was added and incubated (Pg(-)).
[0091] After incubation, the culture medium was removed, and the cells were rinsed with PBS. FITC (Fluoresceinisothiocyanate)-dextran (4 kDa) adjusted to 1 mg / ml was added, and the cells were incubated at 37°C for 1 hour. The FITC-dextran that passed through the Transwell was recovered, and the fluorescence intensity was measured using a fluorescence microplate reader (Gemini XPS) (excitation light: 490 nm, emitted light: 520 nm). The FITC transmittance when the Pg bacterial solution was added to the control (Pg(+) without material) was set to 100%, and the FITC transmittance when only the culture medium without Pg bacteria was added to the control (Pg(-)) was set to 0%, and the transmittance when the evaluation material treatment was performed at each concentration was calculated by conversion. The results are shown in Figures 1 to 3 It should be noted that the concentration of the evaluation materials in the figure is the concentration of the culture medium containing each material during preparation, and the final concentration (concentration after adding Pg bacteria) is 3 / 4 of this concentration value. In addition, the lower the permeability, the higher the epithelial barrier function.
[0092] like Figures 1 to 3 As shown, EPC-K was confirmed to inhibit the destruction of the oral mucosal epithelial barrier by Pg bacteria. In addition, APM, which is ascorbic acid and its derivatives, and VEA and VEN, which are tocopherol derivatives, did not show the same effect.
[0093] 2. MMP activity assay
[0094] Material preparation
[0095] 5% DMSO was added to the buffer solution attached to each of the following kits, and the resulting solvent was diluted with Figure 4 and 5 Each evaluation material was added at the concentration indicated to prepare an evaluation material solution. The evaluation materials used were EPC-K (dl-α-tocopherol 2-L-ascorbyl phosphate diester potassium salt), VC (ascorbic acid), VEA (tocopherol acetate), and VEN (tocopherol nicotinate).
[0096] Enzyme activity assay
[0097] The activity of MMP-8 (neutrophil collagenase) was evaluated by the following method using an MMP-8 fluorimetric drug discovery kit (Enzo Life Sciences, Inc., BML-AK415-0001), and the activity of MMP-1 (fibroblast collagenase) was evaluated by the following method using an MMP-1 fluorimetric drug discovery kit (Enzo Life Sciences, Inc., BML-AK405-0001).
[0098] 0.1 μl of MMP-8 and 69.9 μl of the buffer solution attached to the kit, or 0.2 μl of MMP-1 and 69.8 μl of the buffer solution attached to the kit were mixed into 20 μl of each prepared evaluation material solution, and the mixture was reacted at 37° C. for 60 minutes. At this time, a sample in which an equal amount of buffer was added without adding the evaluation material was prepared as a positive control (Cont.). In addition, a sample in which an equal amount of buffer was added without adding MMP-8 or MMP-1 was prepared in order to measure the background when only the substrate was used (NC).
[0099] The fluorescent substrate included in the kit was diluted 10 times with a buffer solution, and 10 μl was added to the solution after the reaction for 60 minutes. After addition, MMP-8 was reacted at 37°C for 20 minutes, and MMP-1 was reacted at 37°C for 60 minutes, and then the fluorescence intensity of the excitation light: 328 nm and the emitted light: 420 nm was measured. The value obtained by subtracting the fluorescence intensity of only the substrate (NC) from the fluorescence intensity of the positive control sample (Cont.) was set to 100%, and the ratio of the value obtained by subtracting the fluorescence intensity of only the substrate (NC) from the fluorescence intensity of the sample to which each evaluation material solution was added was calculated as the enzyme activity. It should be noted that MMP-8 has a higher reactivity than MMP-1 in terms of the reactivity of the reaction substrate included in each kit. Therefore, in this experiment, in order to conduct the study under conditions where the reactivity is close to the same level, the experiment was carried out at different dilution rates and reaction times for MMP-8 and MMP-1. The results are shown in Figure 4 and 5 It should be noted that the concentration of the evaluation material in the figure is the concentration when the evaluation material is prepared, and the final concentration (the concentration when the fluorescence intensity is measured) is 1 / 5 of this concentration value.
[0100] like Figure 4 and 5 As shown, it was confirmed that EPC-K inhibited MMP activities (MMP-8 and MMP-1) in a concentration-dependent manner. In addition, similar effects were not confirmed for VEA and VEN, which are derivatives of ascorbic acid and tocopherol.
[0101] 3. Cell Killing Evaluation Test
[0102] Cell culture
[0103] Oral epithelial cell line (Ca9-22 cells) was cultured in 96-well plates until confluence.
[0104] Material preparation
[0105] The evaluation solution was prepared using PBS containing 0.5% DMSO as a solvent so that the final concentration of each surfactant was 1%. The surfactants used were polyoxyethylene (9) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (20) stearyl ether, polyoxyethylene (10) octylphenyl ether, polyoxyethylene glycol monolaurate, sorbitan polyether-60 tetraoleate, diethyl sebacate, and polyoxyethylene hydrogenated castor oil 10.
[0106] Cell killing evaluation
[0107] Add 100 μl of the prepared evaluation solution to the cultured Ca9-22 cells and let stand at room temperature for 10 minutes. After 10 minutes, wash three times with 200 μl of PBS, add WST-1 reagent (Takara Bio), and react for 30 minutes. After the reaction, measure the absorbance at 450nm and 600nm, and calculate the value obtained by subtracting the absorbance at 600nm from the absorbance at 450nm. The value when only the solvent is added for treatment is set to 100%, and the cell survival rate is calculated from the value obtained by the above calculation. The results are shown in Figure 6 and 7 .
[0108] like Figure 6 and 7 As shown in the results, polyoxyethylene alkylphenyl ether (polyoxyethylene (10) octylphenyl ether), polyoxyethylene alkyl ether (polyoxyethylene (9) lauryl ether, polyoxyethylene (20) cetyl ether, polyoxyethylene (20) stearyl ether) and polyoxyethylene fatty acid ester (polyoxyethylene glycol monolaurate) were confirmed to be cytotoxic to cells derived from the oral cavity. On the other hand, other surfactants such as sorbitan polyether-60 tetraoleate, diethyl sebacate, and polyoxyethylene hydrogenated castor oil 10 were confirmed to be not cytotoxic to cells derived from the oral cavity.
Claims
1. An oral composition for human use, comprising an alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate, and excluding an oral composition containing at least one selected from the group consisting of polyoxyethylene alkylphenyl ether, polyoxyethylene alkyl ether and polyoxyethylene fatty acid ester.
2. An anti-periodontal disease composition for human use, comprising an alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate. 3 . The composition according to claim 1 , comprising 0.001 to 1% by mass of dl-α-tocopherol 2-L-ascorbic acid diester phosphate alkali metal salt.
4. The composition according to any one of claims 1 to 3, wherein The alkali metal salt of dl-α-tocopherol 2-L-ascorbic acid diester phosphate is dl-α-tocopherol 2-L-ascorbic acid diester phosphate potassium salt.
5. The composition according to any one of claims 1 to 4, which is used for anti-oral mucositis or anti-dental caries. 6 . The composition according to claim 1 , which is used for enhancing the barrier function of oral mucosal epithelium.
7. The composition according to any one of claims 1 to 6, which is used for inhibiting the activity of matrix metalloproteinases in the oral cavity.
